Phenytoin: protect nerve tissue in MS (type not specified)

Promising

MS (type not specified) · Axonal protection / ion channels / excitotoxicity

A controlled phase 2 trial was positive. Phase 2 trials are small and often measure early markers, so this is a signal, not proof.

Genes linked to MS that these medicines act on: SCN3A

Positive in phase 2 only

Trial	Phase	Participants	Started	Result	Counted
Phenytoin, phase 2	Phase 2	92	2011	Met its main goal Mean 6-month RNFL thickness in the affected eye at 6 months was 81.46 μm (SD 16.27) in the phenytoin group (a mean decrease of 16.69 μm [SD 13.73] from baseline) versus 74.29 μm (15.14) in the placebo group (a mean decrease of 23.79 μm [13.97] since baseline; adjusted 6-month difference of 7.15 μm [95% CI 1.08-13.22]; p=0.021), corresponding to a 30% reduction in the extent of RNFL loss with phenytoin compared with placebo. Paper abstract	Counted

Counted: 1. Will count later: 0. Not counted: 0.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

Assembled by software from public sources.